GlassScriptPhysician profile
Davis Copeland Diamond
NPI 1992332092
$5,372.20
in general payments reported to CMS, 2019-2025
21 companies · $34.69 in 2025
The $34.69 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $1,352 · 2023: $1,955 · 2024: $1,412 · 2025: $34.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.59 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $783.27 | 2021-2024 | |
| Amgen INC. | $703.92 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $485.10 | 2021-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $456.88 | 2022-2024 | |
| Ucb, INC. | $454.90 | 2022-2024 | Cimzia, Bimzelx |
| Abbvie INC. | $454.35 | 2021-2025 | Skyrizi |
| Janssen Scientific Affairs, LLC | $372.78 | 2021-2024 | Tremfya |
| Janssen Biotech, INC. | $255.05 | 2021-2024 | Tremfya, Stelara |
| Almirall LLC | $240.51 | 2023 | Klisyri |
| Pfizer INC. | $205.86 | 2021-2024 | |
| Incyte Corporation | $185.30 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $183.30 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $170.81 | 2023-2024 | Vtama |
| Lilly USA, LLC | $123.67 | 2021-2024 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $103.63 | 2022-2023 | Ilumya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $42.56 | 2021-2024 | Valchlor |
| Organogenesis INC. | $41.24 | 2023-2024 | Puraply |
| Stemline Therapeutics INC. | $34.77 | 2023 | Elzonris |
| Mallinckrodt Hospital Products INC. | $28.22 | 2023 | Uvadex |
| Kerecis Limited | $23.34 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.74 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.